Prescient Therapeutics Limited
AASX:PTX0.06
AUD
+0.00
(-1.75%)
Prescient Therapeutics Limited
ASX:PTX
(Australian Securities Exchange)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Prescient Therapeutics Limited Prescient Therapeutics Limited (ASX:PTX), a clinical-stage oncology company headquartered in Melbourne, Australia and founded in 1986, develops personalised medicine approaches to treat haematological and solid cancers, including targeted therapies and next-generation cell therapies. The company offers PTX-100, a first-in-class small molecule inhibitor of the GGTase-I enzyme that disrupts the oncogenic Ras pathway and targets refractory/relapsed T-cell lymphomas such as cutaneous T-cell lymphoma, mycosis fungoides and Sezary syndrome; OmniCAR, a modular universal CAR-T platform licensed from the University of Pennsylvania and Oxford University that provides control and flexibility over conventional CAR-T therapies by enabling target switching and improved safety; and CellPryme, a cell therapy enhancement platform comprising CellPryme-M to improve CAR-T manufacturing and cell potency and CellPryme-A as an adjuvant to overcome suppressive tumour microenvironments. Prescient Therapeutics collaborates with world-leading institutions including Yale University, University of Pennsylvania, Oxford University, Moffitt Cancer Center and Peter MacCallum Cancer Centre; its technologies target patients with unmet needs in oncology, primarily in Australia, the United States and Europe. In recent developments, PTX-100 receives US FDA Orphan Drug Designation, Fast Track Designation and Investigational New Drug status for T-cell lymphomas, with Phase 2a clinical trials underway since May 2025 following Phase 1b results showing 64% tumour response rate; the European Medicines Agency grants Orphan Drug Designation in November 2025; and the company completes a $9.8 million capital raise in July-August 2025 comprising a $6.8 million Share Purchase Plan and $3 million placement to sophisticated investors to fund PTX-100 advancement toward registration.
Company News
Dow Jones, S&P 500 gain on rate cut hopes as shutdown cancels key inflation, jobs reports
Prescient secures EMA Orphan Drug Designation for PTX-100 in CTCL
'Church-tech' firm Gloo Holdings makes $600m stock market debut
Evion Group welcomes Madagascan Government commitment to mining industry